Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Owing to rapid advancements in NGS (next generation sequencing), genomic alteration is now considered an essential predictive biomarkers that impact the treatment decision in many cases of cancer. Among the various predictive biomarkers, tumor mutation burden (TMB) was identified by NGS and was considered to be useful in predicting a clinical response in cancer cases treated by immunotherapy. In this study, we directly compared the lab-developed-test (LDT) results by target sequencing panel, K-MASTER panel v3.0 and whole-exome sequencing (WES) to evaluate the concordance of TMB. As an initial step, the reference materials (n = 3) with known TMB status were used as an exploratory test. To validate and evaluate TMB, we used one hundred samples that were acquired from surgically resected tissues of non-small cell lung cancer (NSCLC) patients. The TMB of each sample was tested by using both LDT and WES methods, which extracted the DNA from samples at the same time. In addition, we evaluated the impact of capture region, which might lead to different values of TMB; the evaluation of capture region was based on the size of NGS and target sequencing panels. In this pilot study, TMB was evaluated by LDT and WES by using duplicated reference samples; the results of TMB showed high concordance rate (R2 = 0.887). This was also reflected in clinical samples (n = 100), which showed R2 of 0.71. The difference between the coding sequence ratio (3.49%) and the ratio of mutations (4.8%) indicated that the LDT panel identified a relatively higher number of mutations. It was feasible to calculate TMB with LDT panel, which can be useful in clinical practice. Furthermore, a customized approach must be developed for calculating TMB, which differs according to cancer types and specific clinical settings.
Abstract
Owing to rapid advancements in NGS (next generation sequencing), genomic alteration is now considered an essential predictive biomarkers that impact the treatment decision in many cases of cancer. Among the various predictive biomarkers, tumor mutation burden (TMB) was identified by NGS and was considered to be useful in predicting a clinical response in cancer cases treated by immunotherapy. In this study, we directly compared the lab-developed-test (LDT) results by target sequencing panel, K-MASTER panel v3.0 and whole-exome sequencing (WES) to evaluate the concordance of TMB. As an initial step, the reference materials (n = 3) with known TMB status were used as an exploratory test. To validate and evaluate TMB, we used one hundred samples that were acquired from surgically resected tissues of non-small cell lung cancer (NSCLC) patients. The TMB of each sample was tested by using both LDT and WES methods, which extracted the DNA from samples at the same time. In addition, we evaluated the impact of capture region, which might lead to different values of TMB; the evaluation of capture region was based on the size of NGS and target sequencing panels. In this pilot study, TMB was evaluated by LDT and WES by using duplicated reference samples; the results of TMB showed high concordance rate (R2 = 0.887). This was also reflected in clinical samples (n = 100), which showed R2 of 0.71. The difference between the coding sequence ratio (3.49%) and the ratio of mutations (4.8%) indicated that the LDT panel identified a relatively higher number of mutations. It was feasible to calculate TMB with LDT panel, which can be useful in clinical practice. Furthermore, a customized approach must be developed for calculating TMB, which differs according to cancer types and specific clinical settings.
참고문헌 (35)
- Shen T, "Clinical applications of next generation sequencing in cancer : from panels, to exomes, to genomes", Front Genet, 6, pp.215~ (2015)
- Luthra R, "Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges", Cancers (Basel), 7, pp.2023~2036 (2015)
- Ettinger DS, "NCCN Guidelines insights : non-small cell lung cancer, version 2. 2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
- Drilon A, "Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches", Clin Cancer Res, 21, pp.3631~3639 (2015)
- Surrey LF, "Clinical utility of custom-designed NGS panel testing in pediatric tumors", Genome Med, 11, pp.32~ (2019)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Larkin J, "Fiveyear survival with combined nivolumab and ipilimumab in advanced melanoma", N Engl J Med, 381, pp.1535~1546 (2019)
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Yarchoan M, "Tumor mutational burden and response rate to PD-1 inhibition", N Engl J Med, 377, pp.2500~2501 (2017)
- Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
- Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
- Rizvi H, "Molecular determinants of response to anti-programmed cell death(PD)-1 and anti-programmed death-ligand 1(PD-L1)blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing", J Clin Oncol, 36, pp.633~641 (2018)
- Andre T, "Pembrolizumab in microsatellite-instability-high advanced colorectal cancer", N Engl J Med, 383, pp.2207~2218 (2020)
- Marabelle A, "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol, 21, pp.1353~1365 (2020)
- Chalmers ZR, "Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
- Le DT, "PD-1 Blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
- Budczies J, "Optimizing panel-based tumor mutational burden(TMB)measurement", Ann Oncol, 30, pp.1496~1506 (2019)
- Golkaram M, "The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy", PLoS Comput Biol, 16, pp.e1008332~ (2020)
- Hong TH, "Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity", J Immunother Cancer, 8, pp.e001199~ (2020)
- Shim JH, "HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1blockade in advanced non-small-cell lung cancer patients", Ann Oncol, 31, pp.902~911 (2020)
- Heydt C, "Analysis of tumor mutational burden : correlation of five large gene panels with whole exome sequencing", Sci Rep, 10, pp.11387~ (2020)
- Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)
- Kim ST, "Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials", Oncologist, 22, pp.1169~1177 (2017)
- Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY umbrella trial", Cancer Discov, 9, pp.1388~1405 (2019)
- Kim Y, "Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC", J Thorac Oncol, 14, pp.193~202 (2019)
- 이지윤, "Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer", Cancer Research and Treatment, 51(1), pp.408~412 (2019), 대한암학회
- Yun JW, "Elucidation of novel therapeutic targets for acute myeloid leukemias with RUNX1-RUNX1T1 fusion", Int J Mol Sci, 20, pp.1717~ (2019)
- Park YH, "Role of HER2mutations in refractory metastatic breast cancers : targeted sequencing results in patients with refractory breast cancer", Oncotarget, 6, pp.32027~32038 (2015)
- Kim KH, "Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients", Thorac Cancer, 11, pp.2542~2551 (2020)
- Ku BM, "Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer", Invest New Drugs, 38, pp.360~368 (2020)
- 박세훈, "EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation", Cancer Research and Treatment, 52(4), pp.1288~1290 (2020), 대한암학회[DOI]
- Lee HS, "Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer", EBioMedicine, 65, pp.103218~ (2021)
- 이영우, "Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project", Cancer Research and Treatment, 53(1), pp.123~130 (2021), 대한암학회[DOI]
- Wu HX, "Tumor mutational and indel burden : a systematic pan-cancer evaluation as prognostic biomarkers", Ann Transl Med, 7, pp.640~ (2019)
- Fancello L, "Tumor mutational burden quantification from targeted gene panels : major advancements and challenges", J Immunother Cancer, 7, pp.183~ (2019)